NASDAQ:POAI Predictive Oncology Q2 2025 Earnings Report $1.18 +0.02 (+1.72%) Closing price 09/24/2025 04:00 PM EasternExtended Trading$1.10 -0.08 (-6.36%) As of 05:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Predictive Oncology EPS ResultsActual EPS-$0.22Consensus EPS -$0.09Beat/MissMissed by -$0.13One Year Ago EPSN/APredictive Oncology Revenue ResultsActual Revenue$0.00 millionExpected Revenue$1.50 millionBeat/MissMissed by -$1.50 millionYoY Revenue GrowthN/APredictive Oncology Announcement DetailsQuarterQ2 2025Date8/13/2025TimeBefore Market OpensConference Call DateThursday, August 14, 2025Conference Call Time7:00AM ETUpcoming EarningsPredictive Oncology's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Thursday, November 13, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Predictive Oncology Earnings HeadlinesMovano (NASDAQ:MOVE) & Predictive Oncology (NASDAQ:POAI) Financial AnalysisSeptember 20, 2025 | americanbankingnews.comPredictive Oncology partners with nonprofit for AI-powered drug repurposing following difficult second quarterSeptember 7, 2025 | bizjournals.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal. | Brownstone Research (Ad)Predictive Oncology, Every Cure announce strategic collaborationSeptember 4, 2025 | msn.comPredictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer PatientsSeptember 4, 2025 | globenewswire.comPredictive Oncology Finalizes Stock Exchange Purchase AgreementAugust 25, 2025 | theglobeandmail.comSee More Predictive Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Predictive Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Predictive Oncology and other key companies, straight to your email. Email Address About Predictive OncologyPredictive Oncology (NASDAQ:POAI), Inc. is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines. The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells. This platform is complemented by proprietary data integration tools that correlate cellular phenotypes with genetic and molecular profiles. Predictive Oncology also provides custom assay development and contract research services to pharmaceutical and biotech partners seeking to validate drug mechanisms, optimize dosing regimens, or identify novel targets in oncology and related therapeutic areas. Headquartered in St. James, New York, Predictive Oncology serves a global customer base that includes large pharmaceutical companies, emerging biotechs, and academic research institutions. The company began trading on the Nasdaq Capital Market under the ticker POAI in December 2020. Its leadership team brings together expertise in computational biology, oncology research, and data science, positioning Predictive Oncology at the intersection of cutting-edge technology and translational cancer research.View Predictive Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Berkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into Believers Upcoming Earnings NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025)Citigroup (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)The Goldman Sachs Group (10/14/2025)ASML (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
